FDA Announces Plan to Phase Out Some Animal Testing
By Stephanie Brown HealthDay Reporter
MONDAY, April 14, 2025 -- The U.S. Food and Drug Administration announced it is shifting away from animal testing in the development of monoclonal antibody therapies and other drugs, favoring more effective, human-relevant methods.
The new strategy aims to enhance drug safety and expedite the evaluation process. It also seeks to decrease animal experimentation, lower research and development costs, and as a result, reduce drug prices.
To achieve these ends, the FDA will use computer modeling and artificial intelligence (AI) to predict a drug’s behavior and promote the use of lab-grown human organoids (tiny, self-organized three-dimensional tissue cultures derived from stem cells) and organ-on-a-chip systems that mimic human organs to test drug safety.
The new regimen is set to launch immediately for investigational new drug applications. To assess efficacy, the agency will start utilizing preexisting, real-world safety data from countries with comparable regulatory standards, where the drug has already undergone human studies.
"For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use," FDA Commissioner Martin A. Makary, M.D., M.P.H., said in a statement. "By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices. It is a win-win for public health and ethics."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury
TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The...
Everyday Digital Tech Is Protecting Seniors' Brain Health, Study Says
TUESDAY, April 15, 2025 -- It’s a common notion that overuse of smartphones, tablets, laptops and other digital devices is rotting people’s minds. But the opposite...
ERs Treat A Gunshot Wound Every Half-Hour
TUESDAY, April 15, 2025 -- U.S. emergency room doctors treat a gunshot wound every half-hour, a new study has found. What’s more, firearm injuries appear to follow specific...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.